logo
logo

Oncorena Secures Financing Of The Company'S Continued Development Of Orellanine, A Potential Breakthrough Therapy For Advanced Renal Cancer

Dec 23, 2021•over 3 years ago
LundOtherData And Analytics

Description

Oncorena, developing a potential breakthrough therapy for advanced renal cancer, receives a capital injection of MSEK 66 from one of the company's principal shareholders together with two new investors. Under the terms of the agreement, Oncorena can receive an additional SEK 94 million in the future. The capital will primarily fund Oncorena's first clinical study, a phase I/II study with orellanine in patients with advanced kidney cancer undergoing dialysis.

Company Information

Company

Oncorena

Location

Lund, Skåne län, Sweden

About

Oncorena AB is a Swedish pharma company headquartered in Lund. The company develops a new potential breakthrough treatment for patients with advanced kidney cancer. The treatment is based on research at the University of Gothenburg, Sweden, led by professors Börje Haraldsson and Jenny Nyström. The project was initially developed with support from Vinnova, Sweden's Innovation Agency, GU Ventures at the University of Gothenburg and private business angels. Today Oncorena is mainly financed by the investment companies HealthCap, Linc AB, Fåhraeus Startup and Growth AB, as well as the biotech company AQILION AB. For more information, please visit Oncorena ́s website at www.oncorena.com This information was brought to you by Cision http://news.cision.com https://news.cision.com/oncorena-ab/r/oncorena-secures-financing-of-the-company-s-continued-development-of-orellanine--a-potential-breakth,c3477783 The following files are available for download: https://mb.cision.com/Main/20340/3477783/1514128.pdf Press release as PDF https://news.cision.com/oncorena-ab/i/lars-grundemar--ceo-oncorena-ab,c2995855 Lars Grundemar, CEO Oncorena AB SOURCE Oncorena AB